Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 589.2 DKK -20.72% Market Closed
Market Cap: 2.6T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Novo Nordisk A/S
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novo Nordisk A/S
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Total Liabilities & Equity
kr397.4B
CAGR 3-Years
32%
CAGR 5-Years
26%
CAGR 10-Years
19%
H Lundbeck A/S
CSE:HLUN A
Total Liabilities & Equity
kr37.4B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Total Liabilities & Equity
kr6.7B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Total Liabilities & Equity
kr37.9m
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

Market Cap
2.6T DKK
Industry
Pharmaceuticals
Economic Moat
Wide

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Novo Nordisk A/S's Total Liabilities & Equity?
Total Liabilities & Equity
397.4B DKK

Based on the financial report for Sep 30, 2024, Novo Nordisk A/S's Total Liabilities & Equity amounts to 397.4B DKK.

What is Novo Nordisk A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
19%

Over the last year, the Total Liabilities & Equity growth was 32%. The average annual Total Liabilities & Equity growth rates for Novo Nordisk A/S have been 32% over the past three years , 26% over the past five years , and 19% over the past ten years .

Back to Top